AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

A Class of Exceptionally Potent HIV-1 Protease Inhibitors

Summary

Researchers at Purdue University have designed, synthesized, and evaluated a series of exceptionally potent HIV-1 protease inhibitors for the treatment of AIDS and HIV infections. These compounds represent a novel new class of HIV-1 protease inhibitors that include Tp-THF and other substituted ligands in combination with P1, P1', and P2' ligands. These compounds have demonstrated potency against wild-type viruses as well as multidrug resistant strains of HIV-1. Certain compounds exhibit nearly 100 times more potency than the current, standard HIV therapy.

Technology Benefits

Exceptionally potent against wild-type and multidrug resistant strains of HIV-1Potency could reduce dosage requirements while maintaining efficacy

Technology Application

Medical/HealthcarePharmaceuticals

Detailed Technology Description

Arun GhoshGhosh GroupPurdue Chemistry

Countries

United States

Application No.

None

Country/Region

USA

For more information, please click Here